Den här delen av vår hemsida är avsedd för hälso- och sjukvårdspersonal
Arbetar du inom hälso- och sjukvården?Kalciumklorid Abboxia (calcium chloride)
Kalciumklorid Abboxia 0.46 mmol/ml
Solution for injection
Calcium chloride Abboxia is used to treat hypocalcaemia, overdose of calcium channel blockers, hypermagnesaemia or hyperkalaemia in adults and children.*
The solution contains calcium chloride dihydrate, equivalent to 0.46 mmol/ml calcium and 0.91 mmol/ml chloride. It is clear and colourless to slightly coloured, and is given as a slow intravenous infusion, preferably via a central venous catheter. This is because of the risk of vascular irritation and tissue damage during extravasation. During treatment, continuous monitoring of ECG and ionised calcium is recommended to avoid hypercalcaemia. The dose is always adjusted according to the patient's clinical condition and laboratory values.
Calcium chloride Abboxia is contraindicated in hypercalcaemia, hypercalcaemia, hypophosphataemia, severe renal disease, ventricular fibrillation and in patients receiving ceftriaxone. Caution should be exercised when treating with digitalis glycosides and adrenaline, and in patients with conditions such as sarcoidosis.
For full details on dosage, administration, interactions and safety, see the summary of product characteristics (SmPC) and package leaflet on fass.se
Kalciumklorid Abboxia 0.46 mmol/ml
Solution for injection
Pack size: 10 x 10 ml
Order No: 127047
.png?width=300&height=6476&name=Frostpharma%20Kalciumklorid%20Abboxia_grupp%20(1).png)
Abbreviated product information
Calcium chloride Abboxia 0,46 mmol/ml solution for injection (calcium chloride)
Mineral substances, calcium, calcium chloride, ATC code: A12AA07. Rx, EF.
Indications: Treatment of hypocalcaemia, overdose of calcium channel blockers, hypermagnesaemia or hyperkalaemia in adults and children. Contraindications: Hypersensitivity to calcium chloride or to any excipient. Hypercalcaemia, hypercalcuria, hypophosphataemia, severe renal disease, ventricular fibrillation or kidney stones. Co-administration of ceftriaxone, digitalis glycosides or adrenaline. Warnings and precautions: Caution should be observed in sarcoidosis. Do not administer in the same line as calcium-containing solutions, e.g. nutrient solutions. Do not administer intramuscularly, subcutaneously or into perivascular tissue. May cause severe necrotising tissue damage, avoid extravasation. When administered by peripheral route, calcium should be given together with an ongoing glucose drip (without calcium, phosphorus or magnesium). Simultaneous intravenous administration of calcium chloride and phosphate or magnesium carries the risk of precipitation which may become trapped in small vessels and result in emboli. Caution should be exercised where there is an increased risk of hypercalcaemia. Calcium chloride is acidifying. Calcium salts may increase the risk of cardiac arrhythmia, use caution in heart disease. ECG monitoring should be performed to prevent cardiac toxicity associated with hyperkalaemia. Serum calcium levels should be monitored during treatment. Cardiovascular and other systemic side effects may occur as symptoms of acute hypercalcaemia. For further information and prices, see www.fass.se. Based on SmPC approved 2025-05-27. For questions or reporting of side effects or complaints - contact regulatory@frostpharma.com. FrostPharma AB.
